Mycoplasma urealyticum is a type of mycoplasma that is easily detected in the lower genital tract of women (e.g., vulva, vagina, cervix, etc.). In general, cervical swabs and vaginal swabs are the most commonly performed tests in women for mycoplasma culture or nucleic acid testing. However, due to the wide range of people colonized with Mycoplasma solani, the risk of infection needs to be carefully assessed by the physician before determining whether it requires treatment. Alternatively, urine testing is also suitable for RNA detection methods, with the advantages of being non-invasive, convenient, sensitive and specific, and can be used for mass population screening. Some clinical data show that a positive Mycoplasma solani in pregnant women suggests a risk of intra-amniotic infection, which can subsequently lead to fetal growth restriction, malnutrition, and even fetal miscarriage or preterm delivery. In addition, during delivery, Mycoplasma urealyticum can also cause a variety of postpartum diseases in mothers and infants through blood circulation, such as puerperal infection, neonatal pneumonia and neonatal jaundice. Therefore, in order to ensure a good birth, it is recommended to test for Mycoplasma urealyticum as early as possible before pregnancy to achieve early detection and treatment, and to eliminate all kinds of adverse risks from the root.